The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560, administered either intravenously or subcutaneously, in both healthy participants and patients with Alzheimer's disease. Side effects and laboratory results will be monitored.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Your participation could last up to 16 weeks and include 11 visits to the study center, including a 4 day clinical research unit (CRU) stay.
Healthy participants must be of non-childbearing potential
Alzheimer's disease (AD) participants must be at least 50 years of age
Alzheimer's disease (AD) participants must have either mild cognitive impairment (MCI) or mild-to-moderate AD and have a positive PET scan
Participants must not have an increased risk of seizures
To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled. This website is not optimized for your browser, as configured.